Addex Therapeutics: Funding, Investors & Team (Sep 2026)
Addex Therapeutics is a clinical-stage drug organization zeroed in on the turn of events and commercialization of an arising class of novel orally accessible little particle drugs known as allosteric modulators for neurological problems. Allosteric modulators offer a few likely benefits over customary non-allosteric particles and may offer a superior remedial way to deal with regular "orthosteric" little particle or natural medications. Addex's allosteric modulator drug disclosure stage targets receptors and different proteins that are perceived as fundamental for helpful mediation. Addex's lead drug up-and-comer, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a significant enlistment clinical preliminary for Parkinson's illness levodopa prompted dyskinesia (PD-LID). Addex is likewise examining dipraglurant's restorative use in blepharospasm (a kind of dystonia), for which a clinical preliminary is supposed to be started in Q3 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), created in a joint effort with Janssen Pharmaceuticals, Inc., is in a Phase 2a confirmation of idea clinical preliminary for the treatment of epilepsy. Indivior PLC has authorized Addex's GABAB PAM program for the improvement of medication competitors with a concentration in enslavement. Preclinical projects progressing with Addex incorporate GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for gentle neurocognitive problems, mGlu4 PAM for Parkinson's illness and mGlu3 PAM for neurodegenerative issues.
Addex Therapeutics has raised $13.5M across 3 funding rounds on record, the most recent an undisclosed round of $4.3M announced in Sep 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Addex Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2023.
Addex Therapeutics Funding Rounds
Addex Therapeutics raised $4.2M in a Post-IPO Equity announced in Jul 2022.
9 months later, an undisclosed round of $5.0M was announced in Apr 2023.
5 months later, an undisclosed round of $4.3M was announced in Sep 2023.
Addex Therapeutics Founders and Leadership Team
Contact details for the Addex Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Addex Therapeutics Funding Compared to Other Biotechnology Startups
Addex Therapeutics' latest round of $4.3M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Addex Therapeutics in Biotechnology and Plan-les-ouates
Companies Similar to Addex Therapeutics
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Addex Therapeutics Funding FAQs
What does Addex Therapeutics do?
Addex Therapeutics is a clinical-stage drug organization zeroed in on the turn of events and commercialization of an arising class of novel orally accessible little particle drugs known as allosteric modulators for neurological problems. Allosteric modulators offer a few likely benefits over customary non-allosteric particles and may offer a superior remedial way to deal with regular "orthosteric" little particle or natural medications. Addex's allosteric modulator drug disclosure stage targets receptors and different proteins that are perceived as fundamental for helpful mediation. Addex's lead drug up-and-comer, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a significant enlistment clinical preliminary for Parkinson's illness levodopa prompted dyskinesia (PD-LID). Addex is likewise examining dipraglurant's restorative use in blepharospasm (a kind of dystonia), for which a clinical preliminary is supposed to be started in Q3 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), created in a joint effort with Janssen Pharmaceuticals, Inc., is in a Phase 2a confirmation of idea clinical preliminary for the treatment of epilepsy. Indivior PLC has authorized Addex's GABAB PAM program for the improvement of medication competitors with a concentration in enslavement. Preclinical projects progressing with Addex incorporate GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for gentle neurocognitive problems, mGlu4 PAM for Parkinson's illness and mGlu3 PAM for neurodegenerative issues.
How much funding has Addex Therapeutics raised?
Addex Therapeutics has raised $13.5M across 3 rounds on record. The most recent is an undisclosed round of $4.3M announced in Sep 2023.
When did Addex Therapeutics last raise funding?
Addex Therapeutics' most recent funding round on record is an undisclosed round of $4.3M, announced in Sep 2023.
Who is the CEO of Addex Therapeutics?
Tim Dyer is listed as CEO at Addex Therapeutics.
Where is Addex Therapeutics headquartered?
Addex Therapeutics is based in Plan-les-ouates, Geneve, Switzerland.
How many employees does Addex Therapeutics have?
Addex Therapeutics is in the 11-50 employee band.
How does Addex Therapeutics' funding compare to other Biotechnology startups?
Addex Therapeutics' latest round of $4.3M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Addex Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Addex Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.